RxDoctor Payments Data

Pasha Streeter

Adult Health · Monroe, MINPI 1922322684

Payments from drug & device makers

$1,117in general payments, 2019–2025

Across 13 payments — averaging $85.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$244
  • Teva Pharmaceuticals USA, Inc.$180
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • Alkermes, Inc.$125
  • Novo Nordisk$122
  • Johnson & Johnson$113
  • plus $207 from 4 others

What the payments were for

  • Food & beverage$1,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,117 in reported general payments places this provider in the 70th percentile of 527 adult health providers in Michigan.

See all adult health providers in Michigan

Medicare billing

Part B allowed, 2024
$6,393
Medicare patients
53
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl134$182,798
Invega TrinzaPaliperidone Palmitate16$159,253
Abilify MaintenaAripiprazole43$122,541
Invega SustennaPaliperidone Palmitate32$84,941
RexultiBrexpiprazole58$84,213
Risperdal ConstaRisperidone Microspheres27$25,887
Clozapine OdtClozapine24$19,338
Paliperidone ErPaliperidone72$10,597
Clozapine62$6,979
Lurasidone Hcl98$6,435
Aripiprazole205$5,308
Buspirone Hcl236$3,877
Quetiapine Fumarate231$3,569
Risperidone194$3,450
Pimozide11$3,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta$113$270,08175 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$244$206,754101 claims
AbbVieVraylar$58$182,798134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 527 adult health providers in Michigan.

Other adult health in Monroe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →